The 5th Yao Yuan Biotech-Pharma Symposium

posted May 2, 2013, 9:30 PM by Yongli Wang

Dear Colleagues,

 

The pharmaceutical industry has experienced tremendous challenges in recently years due to “patent cliff” threats as well as changes in public and healthcare policies pertaining to how medicine is accessed and paid for. These challenges have caused investors, industrial leaders and scientists to question return on investment, justification of capital spending and career sustainability in R&D.  With a theme of “Transforming Pharmaceutical R&D”, Yao Yuan’s 5th Biotech-Pharma Symposium seeks to gather and inspire scientists at the forefront of discovery and development in the pharmaceutical and biotechnology industries and to provide some context in this period of transition.  This event will be a valuable opportunity for learning amongst professionals, academicians and students, and serves as a platform for discussions around transforming pharmaceutical R&D.  Though primarily intended to be a Midwest regional gathering, e.g., Illinois, Indiana, Iowa and Wisconsin, the Symposium has historically attracted attendees from all areas of the country.

 

Time: May 18, 2013 (Saturday)

Venue: Illinois Science & Technology Park (8045 Lamon Avenue , Skokie, IL60077)

Featured Speakers & Topics:

 

Companion Diagnostics: Consideration of Tumor Heterogeneity

Prof. Mark J. Ratain, Leon O. Jacobson Professor of Medicine and Director of the Center for Personalized Therapeutics, the University of Chicago.

 

Transform Pharmaceutical R&D, Leveraging Open Innovation & Accessing Global Talents

Guoxin Zhu, Ph.D., Executive Director, Eli Lilly.

 

The Discovery of Omecamtiv Mecarbil:  the First, Selective, Small Molecule Activator of Cardiac Myosin

Bradley Morgan, Ph. D., Vice President, Cytokinetics.

 

Discovery of Potent Inhibitors of HCV NS5B Polymerase

John Randolph, Ph.D., Associate Research Fellow, AbbVie.

 

Ponatinib, a third generation BCR-ABL inhibitor approved for leukemia treatment and AP26113, a phase 2 trial compound for ALK+ non-small cell lung cancer treatment

Wei-Sheng Huang, Ph.D., Associate Director, Ariad

 

This conference is free, but please register ASAP to reserve your seats at the following address: http://yypharm.org/?q=5th_symposium. Attached please find the final program and directions to the auditorium.  Thank you and look forward to an exciting symposium.

 

Sincerely

 

Organizing Committee of the 5th Yao Yuan Biotech-Pharma Symposium

Ċ
Yongli Wang,
May 2, 2013, 9:31 PM
Ċ
Yongli Wang,
May 2, 2013, 9:31 PM
Comments